Michelle has worked in the IT Industry for over 10 years as a successful business owner and entrepreneur.  The company she founded, E Com Industries, as the predominant provider of gift cards and owners of www.giftvouchers.com, serviced over 100 major Australian retail brands including Coles Myer and Woolworths expanding operations into the UK, South Africa and New Zealand.  In December 2005, E Com was acquired for $30m cash, returning over 4.6 times investment to shareholders and achieving an IRR of over 30% despite the tech sector crash in 2000.

Post acquisition, Michelle was retained for 12 months to oversee further global expansion of the technology and to undertake new business development activities (off-shore and on-shore) for the acquirer, Retail Decisions PLC.

For three years prior to establishing E Com, Michelle was the Managing Director of Sydney-based computer and web design firm, Networks Beyond 2000.  In addition to her obvious business acumen, Michelle has over 10 years experience in research and development with leading Australian Universities and the Commonwealth Scientific and Industrial Research Organization (CSIRO) where she not only worked in technical areas but also in corporate public affairs.   

Michelle holds a Bachelor of Science (Hons First Class) Degree (University of Sydney) and, as a recipient of both Commonwealth and CSIRO Postgraduate Research Awards completed a Master of Science Degree (University of Sydney) and was awarded her PhD in Applied Science (University of Canberra).  Michelle was the Vice-Chancellor’s nominee and subsequently selected as a Queens Trust representative, has lectured in the Faculty of Applied Science, guest lectured MBA marketing students, was a representative on Academic Board, Faculty Board and the Student Welfare Committee. She also established the Canberra University Postgraduate Association and Canberra Tertiary Tutoring College. 

Michelle currently resides on the Boards of two non-profit organisations: McDonald College, Australia’s leading performing arts school, and Round It Up Australia, a retail based charity.  She is also a member of the Australian Venture Capital Association (AVCAL) and the Entrepreneurs Organisation (EO).

Paul has over recent years assisted and led early-stage and mid stage companies achieve business results in order to attract funding and transform their ideas, technologies and products into sustainable successful businesses.

Paul joined the OneVentures team in June 2008 following the merger of Andover Venture Partners and OneVentures.  Paul was most recently CEO of Medcenter Holdings Inc. a Latin America based on-line pharmaceutical marketing company, a position he held until December 2007.  Previously he served as President and CEO of Orchid Cellmark (Nasdaq:ORCH), the worlds leading provider of genetic testing services, from June 2003.  During his tenure at both companies he developed and implemented major operational and strategic restructurings.  From 1995 to 2001, Dr. Kelly served as CEO of Gemini Genomics (Nasdaq:GMNI), a clinical genomics company which he co-founded in 1995 to discover and commercialize novel gene-based targets.  At Gemini, Dr. Kelly positioned the company for one of the UK’s largest ever biotechnology IPOs, completed strategic corporate acquisitions in Sweden and Canada, and negotiated collaborations with some of the worlds leading research institutions. In 2001, Dr. Kelly oversaw the company’s successful merger with Sequenom (Nasdaq:SQNM), valuing Gemini at over $250M, after which he served for a short period as Executive Vice President.

Before becoming a biotechnology executive, Dr. Kelly had a distinguished career as a researcher and physician specializing in endocrinology at St Vincent’s Hospital, Sydney, Australia.  While serving as a Research Physician at the Garvan Institute for Medical Research in Sydney, Paul authored over 100 scientific publications, largely in genetic epidemiology of common metabolic disorders.

Paul has co-founded a number of other companies in the health sciences and technology arena, including MEARS Technologies, Inc. and AgaMatrix, Inc (a consumer medical device company), all based in the greater Boston area.  Both companies form the basis of Andover Group’s Venture Fund I.

Paul has served on national governmental advisory bodies, as well as on the boards of public and private companies. He served on the Board of Directors of the American Society of Medicine, Law and Ethics from 2005 to 2008.  Dr. Kelly is a graduate of the University of New South Wales where he received his Bachelor of Medicine, Bachelor of Surgery (Honours), and Doctor of Medicine degrees. He is a Fellow of the Australasian College of Physicians and is a Member of the Australian Institute of Company Directors.

Anne-Marie will serve as General Partner, a member of the Investment Committee and Executive Director of the Manager based in Brisbane, a strong source of early stage technology innovation opportunities.

Anne-Marie joined the OneVentures partnership in early 2008 with a view to being a fulltime team member on establishment of the Fund.

OneVentures regards Brisbane as a prime source of early stage technology deal flow. For this reason OneVentures has an office in Brisbane to maintain Anne-Marie’s vital links with government, the private sector and technology entrepreneurs and the substantial local R&D infrastructure including UniQuest (The University of Queensland’s main technology commercialization company), the Institute for Molecular Bioscience, The Australian Institute for Bio-engineering and Nanotechnology, The Institute of Health and Biomedical Innovation and a network of incubators. Examples of successful commercial ventures originating from Queensland include the human papilloma virus vaccine (Gardasil), Peplin Biotech, QRxPharma and Wedgetail Communications. Patent activity in Queensland was 68.5 per million residents for the five years to 2002-3 compared to the Australian average of 64.1.

Anne-Marie most recent role was as CEO, i.lab Incubator Pty Ltd, a company which provides space, coaching, mentoring and other support to 30 early stage technology based companies. i.lab clients have raised over $90-million from the VC and angel communities while in residence. Anne-Marie has over twenty years experience in early stage technology investment, management, operations and business development.During her tenure as CEO at i.lab incubator, Anne-Marie has mentored over 50 companies many of which have gone on to highly successful listings and trade sales. Anne-Marie’s experience includes technology commercialization and incubation, senior management experience in emerging technology sector companies and product development expertise. Prior to joining i.lab Anne-Marie served as Associate Partner, Atlatl Management (a boutique commercialisation consultancy company) and GM Operations and then Manager Corporate Development at UniQuest Pty Ltd (1999-2004). She was Product Development Coordinator with Forbio Research Ltd, a publicly listed forestry biotech company (1997-1999) and General Manager and shareholder Pisces Enterprises, a privately owned and operated plant breeding and propagation facility (1988-1997).

Anne-Marie has a BSc (Hons) and an MBA. She serves on a number of government, industry and university advisory boards and regularly presents on topics related to innovation and entrepreneurship.